Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

254 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The EMPaCT Classifier: A Validated Tool to Predict Postoperative Prostate Cancer-related Death Using Competing-risk Analysis.
Tosco L, Laenen A, Briganti A, Gontero P, Karnes RJ, Bastian PJ, Chlosta P, Claessens F, Chun FK, Everaerts W, Gratzke C, Albersen M, Graefen M, Kneitz B, Marchioro G, Salas RS, Tombal B, Van den Broeck T, Van Der Poel H, Walz J, De Meerleer G, Bossi A, Haustermans K, Van Poppel H, Spahn M, Joniau S; European Multicenter Prostate Cancer Clinical and Translational Research group (EMPaCT). Tosco L, et al. Among authors: laenen a. Eur Urol Focus. 2018 Apr;4(3):369-375. doi: 10.1016/j.euf.2016.12.008. Epub 2017 Jan 17. Eur Urol Focus. 2018. PMID: 28753838 Clinical Trial.
DNA Methylation-Guided Prediction of Clinical Failure in High-Risk Prostate Cancer.
Litovkin K, Van Eynde A, Joniau S, Lerut E, Laenen A, Gevaert T, Gevaert O, Spahn M, Kneitz B, Gramme P, Helleputte T, Isebaert S, Haustermans K, Bollen M. Litovkin K, et al. Among authors: laenen a. PLoS One. 2015 Jun 18;10(6):e0130651. doi: 10.1371/journal.pone.0130651. eCollection 2015. PLoS One. 2015. PMID: 26086362 Free PMC article.
Yttrium-90 radioembolization for the treatment of chemorefractory colorectal liver metastases: Technical results, clinical outcome and factors potentially influencing survival.
Maleux G, Deroose C, Laenen A, Verslype C, Heye S, Haustermans K, De Hertogh G, Sagaert X, Topal B, Aerts R, Prenen H, Vanbeckevoort D, Vandecaveye V, Van Cutsem E. Maleux G, et al. Among authors: laenen a. Acta Oncol. 2016;55(4):486-95. doi: 10.3109/0284186X.2015.1101151. Epub 2015 Dec 1. Acta Oncol. 2016. PMID: 26625262
The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer.
Tosco L, Laenen A, Briganti A, Gontero P, Karnes RJ, Albersen M, Bastian PJ, Chlosta P, Claessens F, Chun FK, Everaerts W, Gratzke C, Graefen M, Kneitz B, Marchioro G, Salas RS, Tombal B, Van den Broeck T, Moris L, Battaglia A, van der Poel H, Walz J, Bossi A, De Meerleer G, Haustermans K, Van Poppel H, Spahn M, Joniau S. Tosco L, et al. Among authors: laenen a. Prostate Cancer Prostatic Dis. 2017 Dec;20(4):407-412. doi: 10.1038/pcan.2017.29. Epub 2017 May 9. Prostate Cancer Prostatic Dis. 2017. PMID: 28485390
Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial.
Tosco L, Laenen A, Gevaert T, Salmon I, Decaestecker C, Davicioni E, Buerki C, Claessens F, Swinnen J, Goffin K, Oyen R, Everaerts W, Moris L, De Meerleer G, Haustermans K, Joniau S; P.E.A.R.L. (ProstatE cAncer Research Leuven). Tosco L, et al. Among authors: laenen a. BMC Cancer. 2018 Apr 2;18(1):354. doi: 10.1186/s12885-018-4275-z. BMC Cancer. 2018. PMID: 29606109 Free PMC article.
Tumor characteristics and outcome by androgen receptor expression in triple-negative breast cancer patients treated with neo-adjuvant chemotherapy.
Jongen L, Floris G, Wildiers H, Claessens F, Richard F, Laenen A, Desmedt C, Ardui J, Punie K, Smeets A, Berteloot P, Vergote I, Neven P. Jongen L, et al. Among authors: laenen a. Breast Cancer Res Treat. 2019 Aug;176(3):699-708. doi: 10.1007/s10549-019-05252-6. Epub 2019 May 20. Breast Cancer Res Treat. 2019. PMID: 31106385
Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors.
Verbiest A, Renders I, Caruso S, Couchy G, Job S, Laenen A, Verkarre V, Rioux-Leclercq N, Schöffski P, Vano Y, Elaidi RT, Lerut E, Albersen M, Oudard S, Fridman WH, Sautès-Fridman C, Albigès L, Wozniak A, Zucman-Rossi J, Beuselinck B. Verbiest A, et al. Among authors: laenen a. Clin Genitourin Cancer. 2019 Oct;17(5):e981-e994. doi: 10.1016/j.clgc.2019.05.009. Epub 2019 May 25. Clin Genitourin Cancer. 2019. PMID: 31229459
254 results